ArticleJournal of clinical microbiology2014
Antifungal drug susceptibility and phylogenetic diversity among Cryptococcus isolates from dogs and cats in North America.
Article in Journal of clinical microbiology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 52 citations in OpenAlex.
- Clinicopathological Features, Treatment Outcome, and the Cryptococcal Antigen Latex Agglutination System Titer in Feline Cryptococcosis Treated with Amphotericin B and Fluconazole.Veterinary sciences · 2025Article
- Cryptococcal meningitis due to Cryptococcus neoformans VNI in a koala (Phascolarctos cinereus) with progressive neurological disease.Australian veterinary journal · 2025Article
- Feline Cryptococcosis due toCase reports in veterinary medicine · 2025Article
- Cryptococcal granulomas of basal ganglia due to Cryptococcus neoformans in a cat: a case report and literature review.The Journal of veterinary medical science · 2023Review
- Article
- A Possible Link between the Environment andInternational journal of environmental research and public health · 2022Article
- Article
- Diagnostic and therapeutic management of Cryptococcosis in a kitten with practical considerations to veterinary pediatric therapeutic approach.Medical mycology case reports · 2021Article
- Review
- Pleiotropy and epistasis within and between signaling pathways defines the genetic architecture of fungal virulence.PLoS genetics · 2021Article
- Population diversity and virulence characteristics of Cryptococcus neoformans/C. gattii species complexes isolated during the pre-HIV-pandemic era.PLoS neglected tropical diseases · 2020Article
- Molecular Epidemiology Reveals Low Genetic Diversity amongPathogens (Basel, Switzerland) · 2020Article
- Expansion of the Emerging Fungal PathogenFrontiers in microbiology · 2020Article
- Multilocus sequence typing (MLST) of clinical and environmental isolates of Cryptococcus neoformans and Cryptococcus gattii in six departments of Colombia reveals high genetic diversity.Revista da Sociedade Brasileira de Medicina Tropical · 2020Article
- The Evolution of Sexual Reproduction and the Mating-Type Locus: Links to Pathogenesis ofAnnual review of genetics · 2019Review
- Genetic Diversity of the Cryptococcus gattii Species Complex in Mato Grosso State, Brazil.Mycopathologia · 2019Article
- Therapy of Non-Dermatophytic Mycoses in Animals.Journal of fungi (Basel, Switzerland) · 2018Review
- Flucytosine resistance in Cryptococcus gattii is indirectly mediated by the FCY2-FCY1-FUR1 pathway.Medical mycology · 2018Article
- Panfungal Polymerase Chain Reaction for Identification of Fungal Pathogens in Formalin-Fixed Animal Tissues.Veterinary pathology · 2017Article
- Cryptococcus gattii molecular type VGII infection associated with lung disease in a goat.BMC veterinary research · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 4 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Molecular types of the Cryptococcus neoformans/Cryptococcus gattii species complex that infect dogs and cats differ regionally and with host species. Antifungal drug susceptibility can vary with molecular type, but the susceptibility of Cryptococcus isolates from dogs and cats is largely unknown. Cryptococcus isolates from 15 dogs and 27 cats were typed using URA5 restriction fragment length polymorphism analysis (RFLP), PCR fingerprinting, and multilocus sequence typing (MLST). Susceptibility was determined using a microdilution assay (Sensititre YeastOne; Trek Diagnostic Systems). MICs were compared among groups. The 42 isolates studied comprised molecular types VGI (7%), VGIIa (7%), VGIIb (5%), VGIIc (5%), VGIII (38%), VGIV (2%), VNI (33%), and VNII (2%), as determined by URA5 RFLP. The VGIV isolate was more closely related to VGIII according to MLST. All VGIII isolates were from cats. All sequence types identified from veterinary isolates clustered with isolates from humans. VGIII isolates showed considerable genetic diversity compared with other Cryptococcus molecular types and could be divided into two major subgroups. Compared with C. neoformans MICs, C. gattii MICs were lower for flucytosine, and VGIII MICs were lower for flucytosine and itraconazole. For all drugs except itraconazole, C. gattii isolates exhibited a wider range of MICs than C. neoformans. MICs varied with Cryptococcus species and molecular type in dogs and cats, and MICs of VGIII isolates were most variable and may reflect phylogenetic diversity in this group. Because sequence types of dogs and cats reflect those infecting humans, these observations may also have implications for treatment of human cryptococcosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.